Stryker announced a major commercial and strategic deal with CMR Surgical, providing roughly $400 million in investment and an option structure that could enable a future acquisition subject to regulatory clearance. Stryker will become the exclusive US sales agent for CMR’s Versius system, while CMR keeps lead development and sales outside the US. The arrangement is positioned around helping Versius Plus accelerate in the US market without forcing a full operating-room workflow overhaul—an issue that matters for hospital adoption of surgical robotics. The deal also signals continued consolidation in medtech robotics, with large device incumbents seeking growth through partnerships with scaling platforms.